Lung cancer: open trials in Argentina

47 open trials have a site in Argentina. Registry data; only the trial team decides who can take part.

NCT05920356
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Trial Treatment · Phase 3 · Amgen
Hospital Británico de Buenos Aires, CABA · Instituto Argentino de Diagnostico y Tratamiento IADT, CABA · Instituto Alexander Fleming, Capital Federal · Centro Oncologico Korben, Capital Federal · Hospital Italiano de La Plata, La Plata · Fundacion Centro Oncológico Riojano Integral para la Investigación y Prevención del Cáncer, La Rioja · Sanatorio Parque SA, Rosario · Fundacion Estudios Clinicos, Rosario · Centro de Diagnostico Investigacion y Tratamiento, Salta · Fundacion ARS Medica, San Salvador de Jujuy · Clínica Viedma, Viedma
Registry updated 2026-11-06
NCT05789082
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Trial Treatment · Phase 1/2 · Hoffmann-La Roche
Hospital Britanico, Buenos Aires · Clinica Adventista Belgrano, Ciudad Autonoma Buenos Aires · Centro Oncologico Riojano Integral (Cori), La Rioja
Registry updated 2026-11-05
NCT06793215
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Trial Treatment · Phase 3 · Hoffmann-La Roche
Hospital Aleman de Buenos Aires, Buenos Aires · Hospital Italiano, Buenos Aires · Centro Oncologico Korben, Ciudad Autonoma Buenos Aires · Clinica Adventista Belgrano, Ciudad Autonoma Buenos Aires · Hospital Britanico, Ciudad Autonoma Buenos Aires
Registry updated 2026-11-05
NCT07144280
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · Pfizer
Instituto Argentino de Diagnostico y Tratamiento IADT, Buenos Aires · Fundacion Respirar, Ciudad Autonoma de Buenos Aires · Hospital Privado Universitario de Córdoba, Córdoba · Centro de Investigaciones Oncológicas Colon, Mar del Plata · Sanatorio Británico, Rosario · Sanatorio Parque, Rosario · COE (Centro Oncológico de Excelencia), San Juan
Registry updated 2026-11-05
NCT07361497
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Trial Treatment · Phase 3 · Bristol-Myers Squibb
Instituto Argentino De Diagnostico Y Tratamiento IADT, Buenas Aires · Clinica Adventista Belgrano, Buenos Aires · Hospital Italiano de Buenos Aires, Buenos Aires · Instituto Medico Especializado Alexander Fleming, Buenos Aires · Instituto de Investigaciones Clinicas Cordoba S.A., Córdoba · Hospital Privado Universitario de Córdoba, Córdoba · Investigaciones Oncologicas C Colon SA, Mar del Plata · Sanatorio Parque Rosario, Rosario
Registry updated 2026-11-05
NCT06452277
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 3 · Bayer
Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC), Buenos Aires · Hospital Italiano de Buenos Aires, Buenos Aires · Fundación CENIT para la Investigación en Neurociencias, Buenos Aires · Centro Medico Privado CEMAIC, Córdoba · Instituto Argentino de Diagnostico y Tratamiento (IADT), TBC · Centro de Investigaciones Clínicas Clínica Viedma, Viedma
Registry updated 2026-11-04
NCT03340506
Dabrafenib and/or Trametinib Rollover Study
Trial Treatment · Phase 4 · Novartis Pharmaceuticals
CABA
Registry updated 2026-11-03
NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Hospital Británico de Buenos Aires-Oncology (Site 0304), Buenos Aires · Hospital Aleman-Oncology (Site 0300), Buenos Aires · Instituto Alexander Fleming (Site 0306), Ciudad Autónoma de Buenos Aires · Centro Privado de RMI Río Cuarto S.A. II (Site 0310), Río Cuarto · Instituto de Oncología de Rosario (Site 0301), Rosario
Registry updated 2026-11-03
NCT06712316
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Trial Treatment · Phase 2/3 · BioNTech SE
Centro de Investigaciones Medicas y Desarrollo LC S.R.L. (LC Investigacion), Buenos Aires · Hospital Italiano de Buenos Aires, Buenos Aires · Instituto Argentino de Diagnostico y Tratamiento IADT, Buenos Aires · Sanatorio Allende, Córdoba · Centro Oncologico Riojano Integral (Cori), La Rioja · Exelsus SRL, San Miguel de Tucumán · Centro de Investigaciones Clinicas. Clinica Viedma S. A, Viedma
Registry updated 2026-11-02
NCT07195695
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Trial Treatment · Phase 3 · Boehringer Ingelheim
Centro Oncologico Korben, CABA · Hospital Británico de Buenos Aires, CABA · Clinica Adventista Belgrano, CABA · Centro de Investigaciones Medicas y Desarrollo LC S.R.L. (LC Investigacion), CABA · Instituto Medico Especializado Alexander Fleming, Ciudad Autónoma de Bs As
Registry updated 2026-11-02
NCT07431827
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) (Site 0309), CABA · Hospital Italiano de Buenos Aires-Clinical Oncology (Site 0306), CABA · Instituto Alexander Fleming (Site 0310), Ciudad Autónoma de Buenos Aires · Sanatorio Parque (Site 0311), Rosario
Registry updated 2026-11-02
NCT07554339
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Hospital Britanico de Buenos Aires (Site 0305), Buenos Aires · Clinica Adventista Belgrano (Site 0304), Ciudad Autonoma de Buenos Aires · Hospital Italiano de Buenos Aires. (Site 0300), Ciudad Autonoma de Buenos Aires · Instituto Alexander Fleming (Site 0301), Ciudad Autonoma de Buenos Aires. · Instituto de Investigaciones Clínicas Mar del Plata (Site 0303), Mar del Plata · Sanatorio Parque (Site 0302), Rosario
Registry updated 2026-11-02
NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Trial Treatment · Phase 2/3 · Mirati Therapeutics Inc.
Aresma - Clinica Adventista Belgrano, Belgrano · Instituto Medico Especializado Alexander Fleming, Buenos Aires · Local Institution - 007-5002, Buenos Aires · Fundacion Respirar, Ciudad Autonoma de Buenos Aires · Local Institution - Unk043, Ciudad Autonoma de Buenos Aires · Instituto Argentino de Diagnóstico y Tratamiento, Ciudad Autónoma de Buenos Aires · Instituto Oncologico de Cordoba (IONC), Córdoba · Local Institution - 007-436, Pergamino · Local Institution - Unk033, Porto Alegre · Local Institution - Unk020, Río Cuarto · Sanatorio Parque, Rosario · Instituto de Oncología de Rosario, Rosario · Centro Oncologico Korben, San Pedro · Local Institution - 007-433, Viedma
Registry updated 2026-10-30
NCT06623422
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Fundacion Intecnus (Site 2456), Bariloche · Instituto Medico Especializado Alexander Fleming (Site 2457), Buenos Aires · CEMIC (Site 2454), Caba. · Hospital Italiano de Buenos Aires-Clinical Oncology (Site 2459), Ciudad Autonoma de Buenos Aires. · Instituto Oncologico de Cordoba -IONC (Site 2455), Córdoba · Centro Médico IPAM (Site 2452), Rosario
Registry updated 2026-10-30
NCT04928846
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · AbbVie
Instituto de Oncologia Angel H Roffo /ID# 231499, Buenos Aires · LC Investigacion /ID# 239880, Buenos Aires · Centro Médico Austral /ID# 239860, Ciudad Autonoma Buenos Aires · Cemic /Id# 231486, Ciudad Autonoma Buenos Aires · Hospital Britanico de Buenos Aires /ID# 231495, Ciudad Autonoma de Buenos Aire · Centro de Investigaciones Clinicas Clinica Viedma S.A. /ID# 232339, Viedma
Registry updated 2026-10-29
NCT06422143
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Fundacion Intecnus (Site 0205), Bariloche · Hospital Aleman-Oncology (Site 0202), Buenos Aires · Instituto Alexander Fleming (Site 0203), Ciudad Autónoma de Buenos Aires · Instituto de Investigaciones Clínicas Mar del Plata (Site 0200), Mar del Plata · Instituto Médico Río Cuarto (Site 0204), Río Cuarto · Sanatorio Parque (Site 0201), Rosario
Registry updated 2026-10-29
NCT06692738
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · AstraZeneca
Buenos Aires · CABA · La Plata · Pilar · Rosario
Registry updated 2026-10-29
NCT04557449
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Trial Treatment · Phase 1/2 · Pfizer
Fundacion Respirar, Buenos Aires · Fundacion CENIT para la Investigacion en Neurociencias, Caba · Hospital Británico de Buenos Aires, Ciudad Autónoma de Buenos Aires · Clínica Universitaria Reina Fabiola, Córdoba · Fundación CORI para la Investigación y Prevención del Cáncer, La Rioja
Registry updated 2026-10-28
NCT06627647
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Trial Treatment · Phase 3 · AstraZeneca
Buenos Aires · CABA · La Plata · Pilar · Rosario
Registry updated 2026-10-28
NCT07472517
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Trial Treatment · Phase 3 · Boehringer Ingelheim
Clinica Adventista Belgrano, CABA · Hospital Británico de Buenos Aires, CABA · Clinica Privada Independencia, Munro · Sanatorio Allende S.A., Nueva Córdoba · Sanatorio Parque S.A., Rosario
Registry updated 2026-10-28
NCT07739966
A Study of DS-3939a in Participants With Solid Tumors
Trial Treatment · Phase 1/2 · Daiichi Sankyo
Instituto Alexander Fleming, Buenos Aires · Instituto Oncologico de Cordoba Ionc Fundacion Richardet Longo, Córdoba · Sanatorio Parque, Rosario · CER SAN JUAN - Centro Polivalente de Asistencia e Investigación Clínica, San Juan · Clinica Viedma S.A., Viedma
Registry updated 2026-10-28
NCT06772623
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Trial Treatment · Phase 1/2 · AbbVie
Fundacion Respirar /ID# 281039, Buenos Aires · Centro Oncologico Korben /ID# 281460, Buenos Aires · Instituto Alexander Fleming /ID# 282704, Ciudad Autonoma de Buenos Aire
Registry updated 2026-10-27
NCT06875310
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Trial Treatment · Phase 3 · Mirati Therapeutics Inc.
Hospital Italiano de Buenos Aires, ABB · Clinica Adventista Belgrano, CABA · Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires · IDIM - Instituto de Investigaciones Metabólicas, Ciudad de Buenos Aires · Hospital Universitario Austral, Pilar · Sanatorio Plaza, Rosario
Registry updated 2026-10-27
NCT06345729
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Centro de Oncología e Investigación de Buenos Aires (Site 0308), Berazategui · AUSTRAL MEDICAL CENTER (Site 0302), CABA · Centro Oncologico Korben (Site 0304), CABA · Instituto de Investigaciones Clínicas Mar del Plata (Site 0300), Mar del Plata · Sanatorio Parque (Site 0301), Rosario · Fundacion Estudios Clinicos (Site 0306), Rosario · Clinica Viedma S. A (Site 0307), Viedma
Registry updated 2026-10-26
NCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Instituto Alexander Fleming (Site 0311), Ciudad Autónoma de Buenos Aires · Hospital Italiano de Cordoba (Site 0308), Córdoba · CEMAIC (Site 0309), Córdoba · Instituto de Investigaciones Clínicas Mar del Plata (Site 0300), Mar del Plata
Registry updated 2026-10-26

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error